BNF 83 (British National Formulary) March 2022

Product Information

The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some recent key changes that have been made to BNF content.

BNF 83 (British National Formulary) March 2022 PDF Free BNF 83 (British National Formulary) March 2022 PDF Free

Selective serotonin re-uptake inhibitors: breast-feeding advice for all drugs in class and individual drug monographs updated (see examples in fluoxetine and sertraline). Aminoglycosides: pre-treatment screening advice on genetic testing for aminoglycoside exposure posing risk to hearing (advice in relevant monographs; see example in gentamicin). Tranexamic acid [update to dosing for prevention and treatment of significant haemorrhage following major trauma]. A significant investment from National Institute for Health and Care Excellence (NICE) ensures that, with our partners BMJ Group and Royal College of Paediatrics and Child Health, we support NHS health professionals in the UK with unlimited access to BNF content online through MedicinesComplete, via the BNF + BNFC app and in print. This edition of BNF continues to broadly follow the high-level structure of previous editions of BNF. Preliminary material, including information on how to use the BNF, significant changes to the content in each edition, and guidance on various prescribing issues (eg, prescription writing, use of intravenous medications, particular considerations for special patient populations). Chapters, which contain drug monographs that describe the uses, dosages, safety issues, and other considerations involved in drug use; drug class monographs; and treatment summaries, which include guidance on medication selection. Treatment monographs and summaries are divided into chapters based on specific aspects of medical care, such as Chapter 5, Infections, or Chapter 16, Emergency Treatment of Poisoning; or drug use related to a particular body system, such as Chapter 2, Cardiovascular.

Clarithromycin [update to include dosing for prevention of invasive group A streptococcal infection in children from 6 months old and adults]. The cover image preview of BNF 83 (British National Formulary) March 2022 PDF Looks Something like this:

BNF 83 (British National Formulary) March 2022 - Pharmacy Books BNF 83 (British National Formulary) March 2022 - Pharmacy Books

Specialist drug” monographs within BNF Publications: identification and reduced level of detail, see How to use BNF Publications online. Drugs that cause hepatotoxicity, drugs with CNS depressant effects, and drugs that increase serum potassium: pharmacodynamic effects drug groups revalidated and updated; see Appendix 1 interactions. Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. At Medicalstudyzone.com, we take user experience very seriously and thus always strive to improve. We hope that you people find our blog beneficial! The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines Related articles

Oral iron: updated dosing and monitoring advice for iron-deficiency anaemia based on British Society of Gastroenterology guidelines (advice in ferrous sulfate, ferrous sulfate with ascorbic acid, ferrous fumarate, ferrous gluconate, ferric maltol, sodium feredetate; see example in ferrous sulfate). Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease [MHRA/CHM advice]. Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia [MHRA/CHM advice] (advice in calcium gluconate).

BNF Publications Online Access British National Formulary | BNF Publications

Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality [MHRA/CHM advice] (advice in abrocitinib, baricitinib, filgotinib, tofacitinib, upadacitinib; see example in tofacitinib). This update contains 6 significant changes, 1 dose change, 2 new monographs, 1 new preparation, 4 deleted monographs, and 1 deleted preparation.Controlled drugs and drug dependence: updated guidance on prescription requirements for Schedule 2 and 3 Controlled Drugs.

Bnf 83 British National Formulary March 2022 Book PDF Bnf 83 British National Formulary March 2022 Book PDF

Direct-acting oral anticoagulants (DOACs): reminder of dose adjustments in patients with renal impairment [MHRA/CHM advice] (advice in apixaban, dabigatran etexilate, edoxaban, and rivaroxaban; see example in dabigatran etexilate). Vaccines update [classifications changed to Vaccines, live or Vaccines, inactivated and non-replicating]. Adrenaline/epinephrine: recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure [National Patient Safety Alert advice]. Independent, authoritative guidance on best practices that enables you to select safe and effective medications Drugs that cause first dose hypotension, drugs that cause peripheral neuropathy, and drugs that cause hyponatraemia: pharmacodynamic effects drug groups revalidated and updated; see Appendix 1 interactions.Hyoscine hydrobromide patches ( Scopoderm® 1.5 mg patch or Scopoderm® TTS patch): risk of anticholinergic side effects, including hyperthermia [MHRA/CHM advice]. Vaccines update: restructure of Typhoid vaccine monograph—creation of monographs for typhoid vaccine (live) and typhoid vaccine (inactivated). Drugs that cause thromboembolism: pharmacodynamic effects drug group deleted from Appendix 1 interactions.